BPC-157
BPC-157 (short for Body Protection Compound-157) is a synthetic 15-amino-acid peptide sequence originally identified as a partial fragment of a protein present in human gastric juice. It is not derived from a naturally circulating hormone and is not manufactured as an approved pharmaceutical. Laboratory versions used in research are chemically synthesized peptides rather than extracts of any FDA-cleared product.
Patients typically encounter BPC-157 through fitness and recovery forums, where it is discussed as a research compound linked to tendon, ligament, and gut healing in animal studies. The gap between how it is marketed online and what has actually been demonstrated in humans is part of why physicians want to discuss it directly rather than let a patient rely on secondhand claims. Some ask because they have already purchased it from an unregulated source and want an honest read on the evidence.
Patient options
- BPC-157 patient options are shown by the product panel on this page. If the panel does not load, the direct portal link below opens the same product.
- A physician decides medical appropriateness only after a full evaluation. Nothing on this page is a prescription or medical advice.
What the research actually shows
- Rodent models of tendon and ligament injury
- Rodent and rat models of gastric and intestinal lining injury
- Cell-culture studies of fibroblast and endothelial cell migration
- Animal models of nerve injury and vagal signalling
- Structure-activity work characterizing the peptide fragment itself
What we know about human evidence
- No adequately controlled human clinical trials of BPC-157 for any indication have been identified in the peer-reviewed literature.
- Reports of human use are almost entirely anecdotal, self-reported, or drawn from unregulated online sourcing rather than clinical research settings.
- Because there is no established human dosing or safety profile, statements about effectiveness or safety in people are extrapolations from animal data, not demonstrated findings.
- The absence of human trials means long-term safety, immunogenicity, and interaction risks in people remain essentially uncharacterized.
Important unanswered questions
- Whether any preclinical finding translates into a measurable benefit in humans at any exposure level.
- What an appropriate human exposure range would be, since none has been established in controlled trials.
- Long-term safety, including effects with repeated or extended exposure in people.
- How BPC-157 interacts with other medications or existing health conditions in humans.
- The purity, identity, and consistency of unregulated products marketed under this name.
- Whether the FDA's 2023 bulk-substance action will change over time as more data becomes available.
Safety considerations
- No established human safety profile exists, so risks of allergic reaction, immune response, or organ effects are not well characterized.
- Products sold online as BPC-157 are frequently unregulated, with no assurance of correct identity, purity, or sterility.
- The FDA's 2023 safety determination reflects real regulatory concern about compounding this substance, not a cleared path to safe use.
- Any injectable research-grade product carries injection site and contamination risks when not compounded under pharmaceutical quality controls.
- Interaction risk with other medications is essentially unstudied in humans.
- Marketing claims of healing or recovery benefits are not supported by human trial evidence and should be treated skeptically.
Questions for your physician
- What does the current lack of human trial data mean for me specifically?
- How did the FDA's 2023 bulk-substance determination change what a compounding pharmacy can legally prepare?
- What evidence-based alternatives exist for the tissue or gut concern I'm asking about?
- How would you evaluate the quality or legitimacy of a product marketed as BPC-157?
- What symptoms would mean I should stop and seek care immediately?
- Is there any legitimate research pathway through which this could become available to me?
More from GOAL.MD
Public records
Questions? Call 314-907-3103 or toll-free 800-674-2855, Monday–Friday, 9am–5pm Central, or email customer@jellyfish.md.
BPC-157 is investigational, with no adequately controlled human trials published. See the research limits, safety considerations and questions for your physician, plus current patient options at GOAL.MD.